Surface glycan targeting for cancer nano-immunotherapy
Surface glycan targeting for cancer nano-immunotherapy
复制标题
DOI：
10.1016/j.jconrel.2022.01.004
复制
发表时间：
2022-01-18
影响因子：
10.8
通讯作者：
Choi, Jonghoon
中科院分区：
文献类型：
--
作者：
Choi, Yonghyun;Kim, Jiwon;Choi, Jonghoon
癌症免疫治疗是一种新兴的癌症治疗策略。FDA批准的大多数免疫治疗剂调节先天免疫系统和相关的免疫细胞活性，特别是免疫抑制剂由于其显著的临床潜力而改变了癌症免疫治疗领域。然而，先前报道的免疫治疗剂已经表现出不期望的副作用，包括自身免疫毒性和炎症。因此，控制这些有害反应并设计能够精确靶向特定区域的治疗方法对于提高癌症免疫治疗的疗效至关重要。最近的研究报道，癌细胞利用聚糖-免疫检查点相互作用来调节免疫细胞活性。因此，识别癌症聚糖部分如唾液酸聚糖可以改善免疫细胞的抗癌活性。在这篇综述中，我们讨论了癌症免疫治疗的最新进展，涉及聚糖和基于纳米材料辅助局部给药系统的聚糖靶向技术。
Cancer immunotherapy is an emerging therapeutic strategy for cancer treatment. Most of the immunotherapeutics approved by the FDA regulate the innate immune system and associated immune cell activity, with immune check inhibitors in particular having transformed the field of cancer immunotherapy due to their significant clinical potential. However, previously reported immunotherapeutics have exhibited undesirable side effects, including autoimmune toxicity and inflammation. Controlling these deleterious responses and designing therapeutics that can precisely target specific regions are thus crucial to improving the efficacy of cancer immunotherapies. Recent studies have reported that cancer cells employ glycan-immune checkpoint interactions to modulate immune cell activity. Thus, the recognition of cancer glycan moieties such as sialoglycans may improve the anticancer activity of immune cells. In this review, we discuss recent advances in cancer immunotherapies involving glycans and glycan-targeting technologies based on nanomaterial-assisted local delivery systems.